A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; Etoposide; Rituximab; Topotecan; Vincristine
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 29 May 2018 Planned primary completion date changed from 25 Apr 2021 to 31 Dec 2021.
- 30 Nov 2017 Planned initiation date changed from 4 Sep 2017 to 6 Dec 2017.
- 29 Nov 2017 Planned End Date changed from 6 Dec 2021 to 7 Apr 2022.